

Reference:	FOI.20766.26
Subject:	Alzheimer's Disease
Date of Request:	17 June 2026

Request and response:

1. I would be grateful if you could send the most recent planning document(s) for the diagnosis and treatment of **Alzheimer's Disease**, whether these are from the Health Board, Integrated Care Board (ICB), or the region. I am particularly interested in planning documents that cover lumbar punctures (CSF) and Blood Biomarker testing.

Hywel Dda University Health Board (UHB) confirms there are no planning documents in place that cover the diagnosis and treatment of Alzheimer's Disease.

2. To what extent are there plans for service improvement of diagnosing **Alzheimer's Disease**?

	Yes / No
Implementation of plans has started	No
A plan exists and implementation has not started	No
A plan is being developed	No
There is no plan	Yes
Other – please state	No

3. Are the plans for service improvement of diagnosing **Alzheimer's Disease** related to:

	Yes / No
Cognitive assessment services	Yes
Biomarker services	No
None / neither	Not applicable – see response to q1

4. Which of the following services does the Health Board have in place in preparation for increased service delivery for **Alzheimer's Disease**?

	Related to administration of lumbar punctures Yes / No	Related to Blood Biomarker testing Yes / No
Budget	No	No
People	No	No

Training	No	No
Clinic space / capacity	No	No
Governance arrangements	No	No

5. How many lumbar puncture procedures to test for **Alzheimer's Disease** were performed in the last three-month period for which data are available?

	Number of procedures
Number of lumbar punctures	0

6. Please provide the number of BBM tests for **Alzheimer's Disease** conducted over the last three-months, regardless of whether they were carried out within your organisation or sent to an external pathology laboratory.

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of Blood Biomarker tests	0	0	0

7. Which of the following biomarker tests were used to detect **Alzheimer's Disease**?

	Yes / No
pTau181 immunoassay tests	No
pTau217 immunoassay tests	No

8. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers samples for **pTau181** and **pTau217** immunoassay testing for **Alzheimer's Disease**?

The UHB does not refer onwards to other organisations for pTau181 and pTau217 immunoassay testing for Alzheimer's Disease.

Full name of Trust or organisation(s)
Not applicable.

9. How many **pTau181** immunoassay tests were conducted to test for **Alzheimer's Disease** in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau181 tests	0	0	0

10. Is **pTau181** testing for Alzheimer's Disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau181 Testing associated with clinical trial activity	No

11. How many **pTau181** immunoassay tests were conducted for **Alzheimer's Disease** as part of a clinical trial?

Number of pTau181 tests	0
-------------------------	---

12. How many **pTau217** immunoassay tests were conducted to test for **Alzheimer's Disease** in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau217 tests	0	0	0

13. Is **pTau217** testing for **Alzheimer's Disease** linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau217 Testing associated with clinical trial activity	Yes

14. How many **pTau217** immunoassay tests were conducted for **Alzheimer's Disease** as part of a clinical trial?

Number of pTau217 tests	The UHB confirms thirty (30) tests were conducted outside of the UHB as part of a clinical trial. This study is not a drugs trial, but tests pTau217 within blood samples.
-------------------------	--